For more than six decades, metformin has been the cornerstone of type 2 diabetes treatment, praised for its affordability, reliability, and safety. Traditionally, doctors and scientists believed its primary purpose was straightforward: lower blood sugar by curbing glucose production in the liver and improving the body’s response to insulin. But a new wave of research is shaking up that long-held view, revealing the brain as a surprising and crucial player in the drug’s effectiveness.
On March 26, 2026, a team of scientists at Baylor College of Medicine, alongside international collaborators, published groundbreaking findings in Science Advances that could fundamentally alter how we understand and treat diabetes. According to the International Business Times, this research uncovers a specific pathway in the brain—centered on a protein called Rap1 in the ventromedial hypothalamus (VMH)—that is essential for metformin’s blood sugar-lowering effects. The discovery not only adds a new chapter to the drug’s story but may pave the way for innovative therapies targeting the brain itself.
“It’s been widely accepted that metformin lowers blood glucose primarily by reducing glucose output in the liver,” explained Dr. Makoto Fukuda, associate professor of pediatrics and nutrition at Baylor and the study’s corresponding author, in comments reported by Economic Times. “Other studies have found that it acts through the gut. We looked into the brain as it is widely recognized as a key regulator of whole-body glucose metabolism. We investigated whether and how the brain contributes to the anti-diabetic effects of metformin.”
To unlock this mystery, the researchers zeroed in on Rap1, a small protein found in the VMH—a region of the brain known to orchestrate energy use and blood sugar regulation. By using genetically modified mice lacking Rap1 in this brain area, the team found that metformin lost its ability to lower blood sugar at clinically relevant doses. Interestingly, other diabetes drugs like insulin and GLP-1 agonists still worked, suggesting metformin’s unique reliance on this brain pathway. When tiny amounts of the drug were injected directly into the brains of diabetic mice, blood sugar levels plummeted—even at doses thousands of times lower than what’s typically given by mouth.
“We found that while the liver and intestines need high concentrations of the drug to respond, the brain reacts to much lower levels,” Dr. Fukuda told Science Alert. The researchers also discovered that metformin activates SF1 neurons in the VMH, which are directly involved in regulating how the body uses energy and sugar. However, this activation only happened when Rap1 was present. In mice missing Rap1, metformin had no effect on these neurons, firmly establishing Rap1’s essential role in the drug’s action.
“This discovery changes how we think about metformin. It’s not just working in the liver or the gut, it’s also acting in the brain,” Fukuda emphasized in multiple interviews. The implications are profound: while a handful of anti-diabetic drugs are known to act on the brain, this research shows that one of the world’s most common diabetes medications has been doing so all along, right under our noses.
The findings are based on laboratory experiments—primarily in mice—and have yet to be confirmed in human patients, as noted by IBTimes. Still, the results open new doors for diabetes care. “These findings open the door to developing new diabetes treatments that directly target this pathway in the brain,” Fukuda said. If future studies validate the same mechanism in people, it could lead to drugs that work more efficiently, with fewer side effects, or that help those for whom metformin is currently ineffective.
But the revelations don’t stop at blood sugar. Metformin has long been associated with other health benefits, and the brain connection might help explain these, too. The drug is regarded as a gerotherapeutic—meaning it may slow certain aging processes. Research suggests it can limit DNA damage, support gene activity linked to longevity, and even reduce wear and tear in the brain. Multiple studies, including one involving over 400 postmenopausal women in 2025, have compared metformin to other diabetes drugs to better understand these broader effects. Some scientists are even exploring whether metformin could lower the risk of Long COVID by protecting the brain.
“In addition, metformin is known for other health benefits, such as slowing brain aging. We plan to investigate whether this same brain Rap1 signaling is responsible for other well-documented effects of the drug on the brain,” Fukuda noted, hinting at a future where metformin—or drugs like it—could be used to fight age-related decline or neurodegenerative diseases.
Of course, no medication is without drawbacks. Metformin’s most common side effects are gastrointestinal, with up to 75% of users experiencing nausea, diarrhea, or discomfort, according to Economic Times. Those with kidney problems are at higher risk for complications. Another concern, highlighted by IBTimes, is vitamin B12 deficiency. Long-term metformin use can reduce the body’s ability to absorb this crucial vitamin, which is vital for healthy nerves and red blood cell production. Symptoms of deficiency can include fatigue, memory problems, and nerve issues like tingling or numbness. Health authorities recommend monitoring vitamin B12 levels in patients taking metformin for several years and supplementing if needed to prevent complications like megaloblastic anemia or peripheral neuropathy.
Despite these caveats, metformin’s safety profile remains strong, and its role as a first-line treatment for type 2 diabetes is well established. Its affordability and long history of use make it accessible to millions worldwide. But as this new research shows, there’s still more to learn about how it works—and how we might harness its power in new ways.
The study’s authors are quick to point out that further research is needed to determine whether the brain pathway they identified is as important in humans as it is in mice. Still, their work has already shifted the conversation. Understanding metformin’s brain-based mechanism could inspire a new generation of therapies that target the nervous system, not just the liver or gut, in the fight against diabetes and perhaps even aging itself.
As the scientific community digests these findings, one thing is clear: after 60 years on the market, metformin is still full of surprises. The humble diabetes drug may have been quietly working in the brain all along, offering hope for future treatments that are smarter, safer, and more effective for millions living with diabetes—and maybe much more.